MA49623A - Composés chimiques - Google Patents

Composés chimiques

Info

Publication number
MA49623A
MA49623A MA049623A MA49623A MA49623A MA 49623 A MA49623 A MA 49623A MA 049623 A MA049623 A MA 049623A MA 49623 A MA49623 A MA 49623A MA 49623 A MA49623 A MA 49623A
Authority
MA
Morocco
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Application number
MA049623A
Other languages
English (en)
Inventor
David Thomas Davies
Martin Everett
Simon Leiris
Nicolas Sprynski
Magdalena Zalacain
Original Assignee
Antabio Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17305973.4A external-priority patent/EP3431474A1/fr
Application filed by Antabio Sas filed Critical Antabio Sas
Publication of MA49623A publication Critical patent/MA49623A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA049623A 2017-07-21 2018-07-20 Composés chimiques MA49623A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305973.4A EP3431474A1 (fr) 2017-07-21 2017-07-21 Composés chimiques
EP18290003 2018-01-08
EP18150903 2018-01-09

Publications (1)

Publication Number Publication Date
MA49623A true MA49623A (fr) 2021-03-17

Family

ID=62952102

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049623A MA49623A (fr) 2017-07-21 2018-07-20 Composés chimiques

Country Status (15)

Country Link
US (2) US11299467B2 (fr)
EP (1) EP3655405B1 (fr)
JP (1) JP2020528412A (fr)
KR (1) KR20200030584A (fr)
CN (2) CN110446708B (fr)
AU (1) AU2018304907B2 (fr)
BR (1) BR112020001327A2 (fr)
CA (1) CA3070036A1 (fr)
ES (1) ES2946917T3 (fr)
IL (1) IL272174A (fr)
MA (1) MA49623A (fr)
MX (1) MX2020000576A (fr)
SG (1) SG11202000217QA (fr)
WO (1) WO2019016393A1 (fr)
ZA (1) ZA202000529B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64679B1 (sr) * 2018-08-09 2023-11-30 Antabio Sas Diazabiciklooktanoni kao inhibitori serinskih beta-laktamaza
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN110878032B (zh) * 2019-10-31 2022-03-15 苏州诚和医药化学有限公司 一种n-苄基乙脒盐酸盐的合成方法
CN110713459A (zh) * 2019-12-04 2020-01-21 西南大学 一类喹啉酮富马来酰胺衍生物的设计合成与应用
KR20210115180A (ko) 2020-03-12 2021-09-27 주식회사 엘지에너지솔루션 에너지 밀도가 향상된 전지 모듈 및 이를 포함하는 전지 팩
CN115745838B (zh) * 2022-10-27 2023-12-22 苏州诚和医药化学有限公司 一种脒类化合物及n-苄基乙脒盐酸盐的合成方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407093A1 (fr) 2000-04-27 2001-11-01 Gary T. Wang Inhibiteurs de phenyle farnesyltransferase substitues
US20020019527A1 (en) 2000-04-27 2002-02-14 Wei-Bo Wang Substituted phenyl farnesyltransferase inhibitors
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
WO2002049632A1 (fr) 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibiteurs de production et de liberation de cytokines inflammatoires
DE10064823A1 (de) 2000-12-22 2002-06-27 Knoll Ag Integrinrezeptorliganden
US6806265B2 (en) 2002-05-16 2004-10-19 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
WO2004026264A2 (fr) * 2002-09-20 2004-04-01 Genelabs Technologies, Inc. Nouveaux composes aromatiques possedant une activite antifongique ou antibacterienne
JP2009513523A (ja) 2003-07-08 2009-04-02 ノバルティス アクチエンゲゼルシャフト ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物
US20080220497A1 (en) 2003-12-24 2008-09-11 Flynn Daniel L Modulation of protein functionalities
CN1810777B (zh) * 2005-01-24 2010-09-29 上海东浩医药生物企业有限公司 一类治疗或预防细菌感染的化合物及其制备方法和用途
JP2009533315A (ja) * 2006-04-10 2009-09-17 ランバクシー ラボラトリーズ リミテッド 抗菌剤
US8039502B2 (en) * 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
NZ583642A (en) 2007-09-04 2012-03-30 Biolipox Ab Bis-aromatic compounds useful in the treatment of inflammation
RU2010123781A (ru) 2007-11-13 2011-12-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Производные 4-(2-фенил)-морфолино)-2-оксопирролидин-1-ил)-n-(тиазол-2-ил)бензолсульфонамида и родственные соединения в качестве модуляторов ионных каналов для лечения боли
EP2220080B1 (fr) 2007-11-13 2012-01-04 Vertex Pharmaceuticals Incorporated Dérivés hétérocycliques utilisés comme modulateurs des canaux ioniques
ES2433744T3 (es) 2008-01-18 2013-12-12 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasas
WO2009094224A1 (fr) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophènes et leurs utilisations
WO2009118596A2 (fr) 2008-03-26 2009-10-01 Glenmark Pharmaceuticals, S. A. Dérivés de phtalimide en tant que modulateurs de trpa1
BRPI0915205A2 (pt) 2008-06-11 2017-03-21 Dana Farber Cancer Inst Inc compostos e composições úteis para o tratamento de malária
US20110294853A1 (en) 2008-09-12 2011-12-01 Benjamin Pelcman Bis Aromatic Compounds for Use in the Treatment of Inflammation
SG172312A1 (en) 2009-01-12 2011-07-28 Akebia Therapeutics Inc Methods for treating vascular leak syndrome
EP2379538A4 (fr) 2009-01-22 2013-01-02 Orchid Res Lab Ltd Composés hétérocycliques en tant qu'inhibiteurs de phosphodiestérase
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
WO2011084882A2 (fr) 2010-01-05 2011-07-14 Contrafect Corporation Procédés et compositions pour une thérapie immunologique améliorée et le ciblage de bactéries à gram-positif
WO2011121505A1 (fr) 2010-03-29 2011-10-06 Piramal Life Sciences Limited Inhibiteurs de cytokine
CN105294690B (zh) 2011-06-17 2018-07-10 辉瑞抗感染公司 制备包括反-7-氧代-6-(磺基氧基)-1,6-二氮杂二环[3,2,1]辛烷-2-甲酰胺的杂环化合物及其盐的方法
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US8895561B2 (en) * 2012-01-18 2014-11-25 Cellceutix Corporation Compounds and methods for treating candidiasis and aspergillus infections
WO2013123444A1 (fr) 2012-02-17 2013-08-22 Amgen Inc. Composés de sulfonyle qui interagissent avec la protéine régulatrice de la glucokinase
US9566310B2 (en) 2012-09-10 2017-02-14 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
EP2968273A4 (fr) 2013-03-15 2016-08-31 Univ Nevada Méthodes de traitement de la dystrophie musculaire
CA2910593C (fr) * 2013-05-03 2018-09-04 Microbiotix, Inc. Potentialisateurs antimicrobiens
WO2014181287A1 (fr) 2013-05-09 2014-11-13 Piramal Enterprises Limited Composés hétérocyclyliques et leurs utilisations
AU2014268477A1 (en) 2013-05-24 2015-11-12 The California Institute For Biomedical Research Compounds for treatment of drug resistant and persistent tuberculosis
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
EP3067355B1 (fr) 2013-10-08 2020-12-16 Meiji Seika Pharma Co., Ltd. Cristaux de dérivé de diazabicyclooctane et procédé de production de cristaux de dérivé de diazabicyclooctane
WO2015110885A1 (fr) 2014-01-21 2015-07-30 Wockhardt Limited Procédé de préparation de (2s,5r)-6-sulpho-oxy-7-oxo-2-[((3r)-pipéridine-3-carbonyl)-hydrazinocarbonyl]-1,6-diaza-bicyclo[3.2.1] octane
JP2017506226A (ja) 2014-02-03 2017-03-02 ウォックハート リミテッド （２ｓ，５ｒ）−１，６−ジアザ−ビシクロ［３．２．１］オクタン−２−カルボニトリル−７−オキソ−６−（スルホオキシ）−モノナトリウム塩を調製する方法
PT3116316T (pt) 2014-03-13 2019-09-30 Assembly Biosciences Inc Moduladores alostéricos da proteína do núcleo da hepatite b
GB2533136A (en) * 2014-12-11 2016-06-15 Antabio Sas Compounds

Also Published As

Publication number Publication date
CA3070036A1 (fr) 2019-01-24
KR20200030584A (ko) 2020-03-20
CN115745910A (zh) 2023-03-07
CN110446708B (zh) 2022-12-02
WO2019016393A1 (fr) 2019-01-24
US20220315546A1 (en) 2022-10-06
ZA202000529B (en) 2023-07-26
AU2018304907A1 (en) 2020-02-06
SG11202000217QA (en) 2020-02-27
IL272174A (en) 2020-03-31
US11299467B2 (en) 2022-04-12
JP2020528412A (ja) 2020-09-24
AU2018304907B2 (en) 2022-11-24
EP3655405C0 (fr) 2023-06-07
MX2020000576A (es) 2020-09-10
CN110446708A (zh) 2019-11-12
BR112020001327A2 (pt) 2020-08-11
ES2946917T3 (es) 2023-07-27
US20200339526A1 (en) 2020-10-29
EP3655405B1 (fr) 2023-06-07
EP3655405A1 (fr) 2020-05-27

Similar Documents

Publication Publication Date Title
MA49701A (fr) Composés immunomodulateurs
MA47131A (fr) Composés benzyl-amide phosphodiamide antiviraux
DK3692040T3 (da) Kemiske forbindelser
FR24C1009I1 (fr) Composés utilisés comme inhibiteurs de kinase
MA42293A (fr) Composés antibactériens
MA44233A (fr) Nouveaux composés
DK3519420T3 (da) Cykliske dinukleotidforbindelser
MA41614A (fr) Composés antiviraux
MA44050A (fr) Nouveaux composés
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
MA52119A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA52948A (fr) Composés
MA51669A (fr) Composés
MA46242A (fr) Composés inhibiteurs de bêta-lactamase
MA49623A (fr) Composés chimiques
DK3298027T3 (da) Anthelmintiske depsipeptidforbindelser
MA53003A (fr) Composés
BR112016029361A2 (pt) novos compostos substituídos por halogênio
MA45221A (fr) Nouveaux composés antibactériens
DK4039675T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
MA50504A (fr) Composés antibactériens
MA44020A (fr) Composés antitumoraux
MA45148A (fr) Composés de carfilzomib pégylés
MA49621A (fr) Composés bifonctionnels